Literature DB >> 30032194

Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.

Elodie Alessandri-Gradt1, Charlotte Charpentier2, Marie Leoz1, Thomas Mourez1, Diane Descamps2, Jean-Christophe Plantier1.   

Abstract

Background: Fostemsavir belongs to the new class of attachment inhibitors (AIs); it inhibits the entry of HIV into CD4+ T-lymphocytes by blocking conformational changes in gp120. This is a promising AI, but previous phenotypic data showed that genetically divergent HIV-1 group O could present natural resistance to this drug. These data were obtained from only two strains, which are not representative of the high intra-group genetic diversity. Moreover, no data are available concerning the other divergent HIV-1 groups (N and P).
Objectives: To further investigate the natural genotypic susceptibility of HIV-1 groups O, N and P (HIV-1 non-M) to fostemsavir, using a large set of sequences.
Methods: The frequency of eight substitutions associated with decreased susceptibility to fostemsavir (L116P, A204D, S375M/H, M426L, M434I, M475I and V506M), was investigated in 111 gp120 sequences from groups O (n = 100), N (n = 9) and P (n = 2).
Results: All HIV-1 group N sequences harboured the three substitutions S375M, M426L and M434I, whereas only 1% and 10% of HIV-1 group O sequences harboured the S375H + M426L and S375H + M434I patterns, respectively. The main genetic profile of HIV-1 groups P and O combined S375H with two atypical substitutions (M426S and M434L). Five group O sequences did not display any of the eight substitutions, but had atypical residues with unknown impact. Conclusions: The genetic polymorphisms in the gp120 of HIV-1 non-M viruses support the hypothesis that these viruses could largely be resistant to inhibition by fostemsavir. Only 5% of group O strains could display full genetic susceptibility. Extensive phenotypic studies are now required.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30032194     DOI: 10.1093/jac/dky271

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.

Authors:  Tao Wang; John F Kadow; Nicholas A Meanwell; Mark Krystal
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.

Authors:  Zaikuan J Yu; Eric P Mosher; Namandjé N Bumpus
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-09-22       Impact factor: 13.820

Review 3.  Mechanisms underlying of antiretroviral drugs in different cellular reservoirs with a focus on macrophages.

Authors:  Stefano Aquaro; Ana Borrajo; Michele Pellegrino; Valentina Svicher
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

4.  Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.

Authors:  Margaret Gartland; Eric Arnoult; Brian T Foley; Max Lataillade; Peter Ackerman; Cyril Llamoso; Mark Krystal
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

Review 5.  Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.

Authors:  Camilla Muccini; Diana Canetti; Antonella Castagna; Vincenzo Spagnuolo
Journal:  Drug Des Devel Ther       Date:  2022-01-25       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.